Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1175 of 5804
-
New heart valve tested in japanese patients: a step forward for aortic stenosis treatment?
Disease control Recruiting nowThe Navitor Japan Study is designed to evaluate the safety and performance of the Navitor™ valve used in combination with the FlexNav™ delivery system in a contemporary, real-world setting.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill could soothe stubborn hives when allergy meds fail
Symptom relief Recruiting nowThe purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are used to stop the body's "allergy alarm system" from o…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to cut dangerous lung Flare-Ups in chronic disease
Disease control Recruiting nowThis study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided i…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill could boost breathing in pompe disease – early trial underway
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental CAR-T therapy takes aim at tough blood cancers
Disease control Not yet recruitingA Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1194D CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New dressing aims to speed healing of diabetic foot ulcers
Disease control Recruiting nowProspective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.
Phase: NA • Sponsor: ConvaTec Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a simple conversation prevent deadly blood clots?
Disease control Recruiting nowVenous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke. Anticoagulant therapy drastically reduces the risk of e…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New gene therapy injection aims to boost prostate cancer radiation results
Disease control Recruiting nowPhase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Phase: PHASE2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Exercise and diet may tame atrial fibrillation in overweight patients
Disease control Recruiting nowAtrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objectiv…
Phase: NA • Sponsor: University of Eastern Finland • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Shockwaves may ease stroke arm stiffness
Symptom relief Recruiting nowStroke is a leading cause of death and disability worldwide. A major complication of stroke is spasticity, marked by increased muscle tone and impaired movement. It affects majority stroke patients and complicates rehabilitation, affecting the upper limb function of survivors. W…
Phase: NA • Sponsor: Gulf Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Rehab program shows promise for long COVID sufferers with chronic illness
Symptom relief Recruiting nowThis study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (…
Phase: NA • Sponsor: Fundación Cardioinfantil Instituto de Cardiología • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Immune-Guided drug timing could cut CMV prevention after transplant
Prevention Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus \[CMV\] infection) based on the recovery of the patient's own immune system. Cytomegalovirus (CMV) is a common and ser…
Phase: PHASE4 • Sponsor: WeiShi • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Hope for Meniere's sufferers: new drug enters final testing phase
Disease control OngoingStudy of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Phase: PHASE3 • Sponsor: Sound Pharmaceuticals, Incorporated • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for stomach cancer patients Who've tried everything?
Disease control Recruiting nowThe aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
Phase: PHASE1, PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug HRS-9813 aims to slow lung scarring in fibrosis patients
Disease control Recruiting nowTo evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo aims to tame Hard-to-Treat transplant complication
Disease control Recruiting nowThis is an open-label phase I study of fostamatinib in combination with ruxolitinib for the treatment of chronic GvHD with a suboptimal response to corticosteroids. The primary objective is to identify a minimum safe and biologically effective dose of fostamatinib when combined w…
Phase: PHASE1 • Sponsor: Stefanie Sarantopoulos, MD, PhD. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug Kylo-11 aims to tackle stubborn heart disease risk factor
Disease control Recruiting nowThis is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Phase: PHASE2 • Sponsor: Kylonova (Xiamen) Biopharma co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Misted chemotherapy shows promise for advanced stomach cancer in early trial
Disease control Recruiting nowThis phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that ha…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowA Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental CAR t therapy takes aim at stubborn AL amyloidosis
Disease control Recruiting nowThis is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
Phase: PHASE1 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC